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Abstract
Objective: The objective of this study was to assess acute patency of a new myocardial revascularization device that connects the left
ventricular cavity to a coronary artery (termed ventriculo-coronary artery bypass, VCAB) thereby providing proximal and distal blood flow
from the site of the anastomosis. Methods: A device made of expanded polytetrafluoroethylene and low density polyethylene was implanted
from the base of the left ventricle to the mid left anterior descending coronary artery (LAD) in 11 juvenile domestic pigs using a beating heart
approach. Flow rates were measured in the distal LAD before and after implant using ultrasonic flow techniques, and patency was assessed at
explant at either 2 or 4 weeks post-implantation. Myocardial perfusion using positron emission tomography (PET) was assessed in a separate
set of pigs (n ¼ 2) revascularized by VCAB 2 weeks post-implant. Results: Net forward flow distal to the implanted device was 73 ^ 15% of
native LAD flow. PET demonstrated that the target myocardium was perfused at 85% of that seen in the remote, control myocardium. Device
patency rate was 80% (4/5) at 2 weeks in one set of pigs and 83% (5/6) at 4 weeks in a second set of pigs. Histologic analysis showed
formation of neointima along the extraventricular segment of the device. Conclusions: This study demonstrates the promise of perfusing
ischemic myocardium using a VCAB approach with a device that provides blood flow both proximal and distal to the anastomosis. Patency of
the transmyocardial device was encouraging at 2 and 4 weeks and warrants further investigation.
q 2003 Published by Elsevier B.V.
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1. Introduction
The viability of myocardial revascularization using
devices to connect the left ventricular cavity to a coronary
artery (termed ventriculo-coronary artery bypass (VCAB))
distal to a coronary occlusion has been documented in the
recent literature using animal models [1–3]. Suehiro et al.
reported acute canine study data which demonstrated that
myocardial flow and function are directly related [3].
Specifically, they reported that a post-implant coronary flow
rate of 70% of baseline native left anterior descending
coronary artery (LAD) flow corresponded to regional wall
motion that was 70% of baseline wall motion. The authors
concluded that directing blood to flow between the left
ventricle and a coronary artery with an occlusion proximal
to the arterial connection could significantly restore
myocardial function to ischemic tissues.
We previously reported promising short-duration
patency of permanently implantable VCAB devices using
the porcine model [1,2]. In these studies performed off-
pump, we demonstrated 91–100% patency at two weeks
and 75% patency at 4 weeks using two different designs that
directed coronary flow exclusively to the distal bed
(unidirectional flow). The unidirectional flow design is
ideal for chronic total occlusions in coronary vessels located
epicardially with access immediately distal to the lesion.
However, for many diseased vessels, a clear need exists for
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a VCAB approach using an implanted device that provides
coronary blood flow both proximal and distal to the
anastomotic site (bi-directional flow). In addition, ideally
a bi-directional device configuration is more flexible and
versatile affording variable length to accommodate most
coronary arteries for revascularization.
Of the few flexible materials historically used as vascular
conduits, expanded polytetrafluoroethylene (ePTFE) was
reported to provide satisfactory results in several limited
clinical trials as a coronary arterial bypass conduit [4–9].
The advantages of ePTFE are that it is easy to handle, thin
walled, pliable, resistant to infection, and not subject to
atherosclerotic degeneration. It also is successful in non-
coronary vascular applications, and can provide for tissue
ingrowth and development of neointima, which may be
important to the achievement of long-term patency [10].
However, thrombosis has been cited as the major reason for
occlusion of synthetic vascular grafts in general [9,10] and
the reason synthetic coronary grafts have not been widely
adopted. There are some potential advantages that bi-
directional VCAB offers that eliminate the risk of
thrombotic occlusion. Specifically, unique hemodynamics
of the investigated device provide peak forward and
retrograde flows that are four times greater than those
seen in the native coronary artery [2]. These high flow rates,
affording transcyclic device washing, and a device design
that minimizes areas for blood stasis provide theoretical
advantages compared with other non-conventional prosthe-
tic aorto-coronary bypass grafts. In addition, since the
transmyocardial insertion site for the designs reported
[2] closely approximates the diseased coronary arterial
segment, only a short length of prosthetic material
(approximately 4 cm) is necessary to accommodate
revascularization. These advantages may result in superior
patency performance. This report documents early patency
results of a newly developed ePTFE and low density
polyethylene (LDPE) bi-directional composite conduit for
performing coronary artery bypass grafting using a VCAB
procedure developed by our group.
2. Materials and methods
2.1. Device design
The bi-directional direct revascularization device (Bi-
DRD) consists of ePTFE reinforced with LDPE through
the transmyocardial segment. External reinforcement rings
are placed along the extraventricular segment of the
device. Device dimensions for animal trials were 3.0 mm
outer diameter, 25 mm long transmyocardial segment, and
40 mm long extraventricular segment (Fig. 1). Expanded
PTFE (Zeus Inc., Orlando, FL) was chosen as the substrate
for the device based on its long history of use in the
cardiovascular environment, i.e. peripheral vascular grafts
and cardiac patches. A portion of the outer surface of
the transmyocardial segment is wrapped in polyethylene
terephthalate (polyester velour, C.R. Bard, Inc., Billerica,
MA) fabric to provide site hemostasis and to encourage
integration of the device within the myocardium. The
device was sterilized using ethylene oxide and degassed for
24 h before use. Tools used in the implantation were either
steam or ethylene oxide sterilized using standard
techniques.
2.2. Surgical technique
All animals were treated according to the ‘Guide for the
Care and Use of Laboratory Animals’ prepared by the
Institute of Laboratory Animal Resources, National
Research Council (National Academy Press, revised
1996). Bi-DRDs were implanted in 13 normal, healthy
domestic Yorkshire-cross pigs less than 1 year of age
weighing 65–75 kg. Pigs were treated with aspirin (325 mg
p.o., Q.D.) and clopidogrel (75 mg p.o., Q.D., Plavixw,
registered trademark of Sanofi~Synthelabo Pharmaceuticals
Inc. licensed to Bristol-Myers Squibb Company, New York,
NY) beginning 3 days prior to the procedure and continuing
until sacrifice. Diltiazem (60 mg p.o.) was administered 1
day prior to and on the morning of surgery. Anesthesia was
induced with a combination of Telazol (tiletamine and
zolazepam, 5 mg/kg, A.H. Robbins Co., Richmond, VA)
and xylazine (5 mg/kg). After intubation, anesthesia was
maintained with 1–2% isofluorane and lidocaine (2 mg/kg)
was used to minimize arterial spasms. A left thoracotomy
and pericardial cradle were performed to expose the left
anterior wall of the heart. Systemic arterial pressure was
monitored using a fluid-filled line inserted into the internal
mammary artery. The animals were systemically hepar-
inized as in a human ‘off-pump’ model (125 U/kg heparin).
A beating heart approach was used during the entire
implant. A 1 cm segment of distal LAD located approxi-
mately 3 cm distal to the anastomotic site was mobilized
circumferentially to place an ultrasonic flow probe (Transo-
nics, model 2.5 or 3.0 SB, Ithaca, NY) for monitoring blood
flow rate using standard techniques. Flow probes were
Fig. 1. Representation of the bi-directional Direct Revascularization Device
(Bi-DRD). Graft consists of ePTFE (a); and rings consist of low density
polyethylene (b). Cuff consists of polyester (c).
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calibrated electronically to zero before each experiment.
Baseline electrocardiogram (ECG), systemic arterial press-
ure, and LAD blood flow rate were recorded for approxi-
mately 4 min (Gould 6600 Smart Case, Gould Instrument
Systems, Inc., Valley View, OH). The heart was then pre-
conditioned using the following sequence: LAD occlusion
– 30 s, recovery – 5 min, LAD occlusion – 2 min, and
recovery – to baseline blood flow rate.
The Bi-DRD was primed with heparinized saline
(2 units/ml heparin) before implantation. The transmyocar-
dial segment of the device was first seated into the left
ventricle (LV) using the method and tools as described. A
purse string suture is placed in the epicardial area where the
device is introduced into the LV to facilitate hemostasis.
Areas with significant coronary branching were avoided. A
metallic inverted L needle guide is superimposed on the
epicardium in the center of the purse string to measure
myocardial wall thickness to choose a device of adequate
length to insure protrusion of the device into the LV
(Fig. 2a). A single port 16 £ 3 1/200 cone ventricular needle
connected to a pressure monitor via a fluid-filled catheter is
inserted through the lumen and advanced through the LV
free wall into the ventricular chamber (Fig. 2a). Penetration
into the LV chamber is confirmed by observing the pressure
tracing on the monitor. The ventricular needle is then
withdrawn until the distal port just penetrates the LV
chamber. A guide wire is advanced through the lumen of the
needle into the LV chamber and the needle is removed (not
shown). LV wall thickness is obtained by measuring the
distance on the needle between the needle guide and the port
at the distal end of the needle.
A 16 F cone-shaped introducing sheath with dilator is
advanced over the wire and through the LV wall (Fig. 2b).
The wire is removed and the ventricular arm of the device is
placed in the sheath by quickly exchanging it for the dilator
(Figs. 2c,d). The sheath, followed by the device handle, are
removed.
The extraventricular segment of the device is trimmed to
length to perform a traditional end-to-side anastomosis. An
off-pump anastomotic stabilizer (Ultima OPCAB System,
Guidant Corp, Indianapolis, IN) is placed around the target
site of the coronary artery for immobilization during the
anastomosis. The proximal LAD is then ligated to simulate a
totally occluded artery. A longitudinal incision (5 mm) is
made in the target site of the LAD and the anastomosis is
performed using 7-O polypropylene suture (Deklenew II,
XT-6, Genzyme Surgical Products Corp., Fall River, MA).
The average implant ischemic time was 10.6 ^ 3.1 min
(n ¼ 11). The implanted device is shown in Fig. 2e.
The flow probe was replaced around the LAD distal to
the implanted Bi-DRD. ECG, arterial pressure, and LAD
blood flow rate were measured, as described, within 10 min
post-implant. A paired t-test was used to compare baseline
flow rates with device flow rates. At the conclusion of the
procedure, the pericardial sac was loosely approximated,
the thoracotomy closed, and the animals recovered. Animals
were sacrificed at 2 or 4 weeks.
2.3. Assessment of myocardial perfusion
In a separate group of pigs (n ¼ 2), DRDs were
implanted in the LAD for assessment of perfusion by
positron emission tomography. Positron emission tomogra-
phy (PET) was performed with an ECAT 953B/31 (CT/Sie-
mens Inc. Knoxville, TN) capable of rapid dynamic imaging
for the generation of time activity curves as described in
McFalls et al. [11]. Briefly, the camera consisted of 16
contiguous rings of bismuth germanate detectors. Cross
sectional images of the heart were recorded with an effective
transaxial resolution of 10 mm. 13N-ammonia images were
acquired at baseline and during a dobutamine stress at 20
mg/kg per min. Using a 3-compartment model, blood flows
were calculated in the LAD and remote posterior wall
regions.
2.4. Animal sacrifice procedure
Pigs were sacrificed using Buthanasiae (Schering-
Plough, Kenilworth, NJ) either 2 or 4 weeks after
implantation. Fifteen minutes before sacrifice the animals
were given 250 units/kg heparin. Using a right thoracotomy,
hearts were quickly exposed and excised. The LAD was
rinsed via perfusion with lactated Ringer’s solution at 100–
120 mmHg until the artery ran clear. McDowell-Trumps
fixative was introduced subsequently and infused for 15 min
at 100 mmHg. Hearts were then placed in 1 l of fresh fixative
and fixed for at least 24 h before handling.
2.5. Light and scanning microscopy
After fixation, the DRD/arterial interface was exposed by
carefully cutting longitudinally, starting 2 cm distal to the
device anastomosis toe and ending 5 mm proximal to the
anastomosis heel. The extraventricular segment was opened
longitudinally. The internal surface was photographed via
photo-stereomicroscopy (Nikon SMZ-U, Nikon, Inc., Mel-
ville, NY). The device was removed from the myocardium
by cutting the polyester cuff longitudinally along the
transmyocardial segment of the device. The tissue blocks,
except for the cuff block, were paraffin embedded, sectioned
and stained with hematoxylin and eosin (H&E). The cuff
block was embedded in plastic and stained with H&E. The
remaining half of the extraventricular segment was
dehydrated through graded ethanol, critical point dried
with CO2 (Autosamdri-814, Tousimis, Inc., Rockville,
MD), coated with 200 A˚ of gold (DV-502A Vacuum
Evaporator, Denton Vacuum, Moorestown, NJ) and exam-
ined via scanning electron microscopy (Hitachi S-450,
Hitachi, Inc., Mountain View, CA) to assess tissue reaction
and neointima formation.
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3. Results
3.1. Coronary flows
Following implantation of the Bi-DRD, the instan-
taneous flow pattern seen distal to the device consisted of
forward flow during systole and retrograde flow during
diastole with no areas of stasis as previously reported [2]
and seen in Fig. 3b. Fig. 3 shows two cardiac cycles of mean
and instantaneous distal LAD flow waveforms before
(Fig. 3a) and after (Fig. 3b) implantation of the device in
one representative animal. Superimposed on the flow
Fig. 2. Illustration of the implant technique. (a) placement of the purse string and measurement of the ventricular wall thickness with a ventricular needle and
needle guide; (b) introduction of the dilator and sheath into the ventricular cavity along the wire; (c, d) placement of the device into the left ventricle and
exchange of the tools; and (e) device fully implanted.
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waveforms are the corresponding systemic arterial pressure
waveforms. This representative animal shown in Fig. 3 had
a net forward flow of 18 ml/min before implantation and 14
ml/min immediately post-implant (Fig. 3b) resulting in
device flow that was 78% of native baseline flow. Analysis
of the net forward flow through the device immediately after
implantation for all animals studied revealed a mean flow
equal to 73 ^ 15% of baseline native LAD coronary flow.
Average peak forward flow measured 144 ^ 59 ml/min, and
average peak retrograde flow measured 269 ^ 31 ml/min
through the device compared with 37 ^ 13 ml/min average
peak forward and28 ^ 10 ml/min average peak retrograde
flow in the native coronary artery (P ¼ 0:00003 for peak
forward flow and P ¼ 0:00001 for peak retrograde flow).
3.2. Survival, patency and tissue reaction
Ten pigs survived to scheduled sacrifice with one animal
in the 4 week group dying 2 days after implantation with a
thrombosed device. This animal required electrical conver-
sion ten times from ventricular fibrillation at implant
resulting in 44 cumulative minutes of ischemia compared
to an average ischemic implant time of 10.6 min for the
study. Five animals each were sacrificed at both 2 and 4
weeks post-implantation. Two weeks after implantation,
four of five devices were patent, and 4 weeks after
implantation five of six devices were patent (including the
early death). The graft that was occluded at 2 weeks failed
due to thrombosis. This graft, which was damaged during
Fig. 3. Instantaneous and mean flow waveforms and systemic arterial pressure (SAP) waveforms before (a); and after (b) implantation of the Bi-DRD.
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suturing to the artery, had caused a severe inflammatory
reaction.
The gross analysis of the DRD/arterial interface of the
four patent devices at 2 weeks showed neointimal
proliferation along approximately 10% of the DRD
originating from the distal anastomosis. Scanning electron
microscopic evaluation revealed minimal accumulation of
platelet/fibrin coagulum on the internal lumen of the DRD.
Insignificant thrombotic deposits were observed on the
aspect of the DRD that protruded into the left ventricle
(Fig. 4). DRDs explanted at 4 weeks showed varying levels
of neointimal proliferation originating from the anastomo-
sis. The entire length of the extraventricular segment was
covered with neointima in one case (Fig. 5). Scanning
electron microscopic evaluation demonstrated an intimal
surface with bumpy or wavy appearing cells consistent with
endothelial cells as the outer-most feature of the neointima
(Fig. 6). The remaining 4-week explants had between 25
and 50% of the length of the extraventricular segment
covered with neointima. The device cuff was found to be
infiltrated with fibroblasts, as reported previously, with a
mild to moderate chronic inflammatory cell response [1].
3.3. Myocardial perfusion
PET assessment of the perfusion in the region of
myocardium subtended by the DRD revealed a mild decline
in perfusion, though with preservation of perfusion at 85%
of baseline (Table 1). With stress, a physiologic increase in
perfusion for the DRD-subtended segment was noted
consistent with controls.
Fig. 4. Gross photograph of endocardial/Bi-DRD interface 4 weeks post-
implant. Note device protrudes into the lumen with no gross biological
deposit.
Fig. 5. LAD/Bi-DRD interface 4 weeks after implantation. LAD in cross-
section. (a) Gross photograph; and (b) Photomicrograph, H&E stain,
original magnification 20 £ . Note no excessive neointimal proliferation at
the vascular interface.
Fig. 6. Scanning electron micrograph of neointimal formation on a 4-week
explanted Bi-DRD, original magnification 500 £ . Note the formation of
non-obstructive, smooth endothelial-like growth into the extraventricular
segment of the device.
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4. Discussion
These data show encouraging results with a bi-
directional DRD for achieving ventriculo-coronary artery
bypass grafting in the porcine model. The results obtained
in this study are comparable with those reported previously
with a rigid titanium conduit having an intracoronary
segment [1,2]. Those studies demonstrated 76 and 74% of
baseline flow, respectively, compared with 73% of baseline
flow seen in this study. This allows perfusion adequate to
maintain contractibility at rest and with dobutamine stress
[1,2]. Suehiro et al. [3] recently reported blood flows
through an unvalved LV-LAD conduit similar in concept to
be only 45% of baseline flow in an acute dog model. The
differences in flows reported between this study and
Suehiro et al. may be related to device design. Suehiro
et al. [3] investigated improving net forward flow by
inhibiting retrograde flow during diastole using a Starling
resistor valve. Our studies have consistently shown that
similar or even superior flows can be obtained with an
unvalved conduit compared to those obtained with a valved
conduit (70%). These studies demonstrate that device
design dramatically affects flow. Incorporating a valve in a
3 mm or smaller diameter conduit is not practical in light
of the fact that no valve smaller than 15 mm internal
diameter has been hemodynamically effective or durable.
Thrombosis due to turbulence created by prosthetic valve
mechanisms is well documented for small caliber devices
in the prosthetic heart valve field [12]. In addition, the
antegrade/retrograde washing of blood, reducing stasis and
deposition, is believed to be a critical component
contributing to long-term patency of a VCAB device as
indicated by these preliminary results.
This study also demonstrates that significant levels of
perfusion both at rest and under stress occur in myocar-
dium subtended by the VCAB device (85% of remote)
compared to myocardium subtended by native coronary
flow. Further, utilizing the present Bi-DRD device,
augmentable flow is preserved and recruitable under stress
conditions similar to control myocardium. It has been
shown that only 20–30% of normal subendocardial flow is
necessary to support systolic function [13]. Importantly,
these devices provide significantly greater flow than that
seen in patients with severe coronary artery disease. Of
clinical relevance are the Hufnagel valve recipients from
the 1950s whose coronaries were perfused during systole
because of valve placement in the descending thoracic
aorta. Significantly, several of these patients lived asymp-
tomatically for up to 18 years [14]. This study and
previously published studies [1–3] support our strategy
that flow delivered to the myocardium during systole with
minimal antegrade coronary flow during diastole, while
less than that which would be predicted for standard
coronary artery bypass grafting, provides adequate levels
of nutritive flow to sustain cardiac function.
In conduits smaller than 4 mm, particularly in coronary
vascular applications, ePTFE has not gained wide accep-
tance [4–9]. Inferior clinical outcomes reported with this
material in coronary vascular applications have been
postulated to be related to a number of factors. The
anastomosis of large diameter ePTFE to coronary arteries
that are only 1.5–2.5 mm outer diameter with resultant poor
hemodynamics due to abrupt diameter change is felt to
contribute to reduced chronic patency. Limited distal
arterial runoff due to the relatively poor condition of the
recipient artery and distal bed predisposes grafts to failure
by thrombosis. Lower trans-conduit flow allowing stasis of
blood contributes to thrombosis of smaller diameter grafts.
Further, the excessive length of synthetic conduit required
for a typical aorto-coronary graft also accelerates and
contributes to a thrombotic response.
Despite the above limitations, encouraging data have
been reported on the use of ePTFE as an aorto-coronary
arterial bypass conduit. Specifically, Emery et al. reported
on the early North American experience with the use of the
Perma-Flow graft, an ePTFE conduit, in patients to 1 year
follow-up [4]. While the numbers were low, they reported
90% early patency and 77% patency at 1 year for 73
coronary side-to-side anastomoses evaluated at 1, 3–8 and
12 month intervals. They concluded that the graft was very
promising for completion therapy. The Perma-Flow graft
has a unique design that results in high flow rates of 250 ml/
min at the aortic proximal end of the graft [4] due to the
creation of a controlled left to right shunt providing
continuous flow through the ePTFE graft. The Bi-DRD
evaluated in the current study also sees high instantaneous
flow rates and no areas of stagnation throughout the cardiac
cycle, similar to the Perma-Flow graft. These data suggest
that ePTFE conduits configured with an appropriate design
allowing for high flows and optimal hemodynamics fares
well in the coronary application.
The Bi-DRD examined in this study addresses several
of the disadvantages observed in the prior use of ePTFE
for coronary surgery in that the diameter of the device
approaches that of the coronary artery (3 mm) and the
hemodynamics of systolic flow results in peak flows four
times greater than native flows with no areas of blood
stasis. In addition, length of the conduit is significantly
shorter in the present Bi-DRD design described (approxi-
mately 4 cm) compared to previous ePTFE conduits,
thereby minimizing adverse blood-material interactions.
Healing of the conduit at 4 weeks in the porcine model
was encouraging with the formation of non-obstructive
Table 1








Baseline (n ¼ 2) 0.91 ^ 0.22 1.07 ^ 0.16 85
Stress (n ¼ 2) 1.21 ^ 0.06 1.46 ^ 0.08 83
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neointima that originated from the host artery on the
lumen of as much as half of the conduit. Finally, thrombus
deposition was not significant on devices that did not
experience technical issues such as infection or severely
compromised flow during implantation associated with
peri-operative ventricular fibrillation.
In conclusion, the novel bi-directional DRD and VCAB
procedure described afford several unique and desirable
revascularization characteristics. This approach allows for
creation of a permanent channel between the left ventricle
and coronary artery providing proximate high flow supply
of oxygenated blood. The Bi-DRD provides both retrograde
and antegrade coronary flow from the site of coronary
anastomosis. This feature maintains perfusion of the full
zone of myocardium distal to a stenosis regardless of the site
of transventricular wall insertion of the ePTFE conduit into
the LV cavity. Further, the present device provides
significant net forward flows, without impairment of flow
reserve under stress conditions. Finally, the present ePTFE
configuration affords good patency, healing and hemocom-
patibility. Results of this study suggest that this device and
surgical technique are promising for coronary bypass
surgery and warrant longer duration studies. The device
may be useful to provide myocardial perfusion in patients
with inadequate conduits or to complete revascularization in
patients who have conditions which obviate standard care
such as porcelain aorta.
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